Roche Holding AG Research and Development Expenses 2010-2023 | RHHBY
Roche Holding AG research and development expenses from 2010 to 2023. Research and development expenses can be defined as an expense arising from studies and product development processes.
Roche Holding AG Annual Research and Development Expenses
(Millions of US $) |
| 2023 |
$15,817 |
| 2022 |
$16,791 |
| 2021 |
$16,192 |
| 2020 |
$13,875 |
| 2019 |
$12,857 |
| 2018 |
$12,363 |
| 2017 |
$11,476 |
| 2016 |
$11,708 |
| 2015 |
$9,971 |
| 2014 |
$10,828 |
| 2013 |
$10,007 |
| 2012 |
$10,193 |
| 2011 |
$9,428 |
| 2010 |
$9,635 |
| 2009 |
$9,120 |
Roche Holding AG Quarterly Research and Development Expenses
(Millions of US $) |
| 2023-12-31 |
|
| 2023-06-30 |
|
| 2022-12-31 |
|
| 2022-06-30 |
|
| 2021-12-31 |
|
| 2021-06-30 |
|
| 2020-12-31 |
|
| 2020-06-30 |
|
| 2019-12-31 |
|
| 2019-06-30 |
|
| 2018-12-31 |
|
| 2018-06-30 |
|
| 2017-12-31 |
|
| 2017-06-30 |
|
| 2016-12-31 |
|
| 2016-06-30 |
|
| 2015-12-31 |
|
| 2015-06-30 |
|
| 2014-12-31 |
|
| 2014-06-30 |
|
| 2013-12-31 |
|
| 2013-06-30 |
|
| 2012-12-31 |
|
| 2012-06-30 |
|
| 2011-12-31 |
|
| 2011-06-30 |
|
| 2010-12-31 |
|
| 2010-06-30 |
|
| 2009-12-31 |
|
| 2009-06-30 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$0.000B |
$65.370B |
|
Basel, Switzerland-based Roche Holding Ltd. is a leading health care company focused on developing and commercializing innovative diagnostic and therapeutic products and services, which enable early detection and prevention of diseases as well as their treatment and monitoring. The company conducts its operations through two segments ' Pharmaceuticals and Diagnostics.Pharmaceuticals: Key focus areas in this segment include Oncology, Virology, Inflammation, Metabolism and Neuroscience. Diagnostics: The Diagnostics Division operates in four segments ' Roche Professional Diagnostics, Roche Diabetes Care, Roche Molecular Diagnostics, and Roche Tissue Diagnostics. In September 2014, Roche acquired InterMune for $8.3 billion and added Esbriet to its portfolio. During the first quarter of 2018, Roche acquired Flatiron Health and Ignyta, Inc.
|
